The LSD1/HDAC dual-target inhibitor for cancer therapy: Challenge and opportunity
- 6 August 2025
- journal article
- review article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 164, 108847
Abstract
No abstract availableKeywords
Funding Information
- Henan Provincial Science and Technology Research Project (252102311176, 242102311236)
- China Postdoctoral Science Foundation (2024M750818)
- National Natural Science Foundation of China (82304286, 82303741)
This publication has 60 references indexed in Scilit:
- A novel dual-epigenetic inhibitor enhances recombinant monoclonal antibody expression in CHO cellsApplied Microbiology and Biotechnology, 2024
- Targeting LSD1 in cancer: Molecular elucidation and recent advancesCancer Letters, 2024
- Unleashing the power of generative AI in drug discoveryDrug Discovery Today, 2024
- Epigenetic clock: A promising biomarker and practical tool in agingAgeing Research Reviews, 2022
- HDAC1/MAO-B dual inhibitors against Alzheimer’s disease: Design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid/o-aminobenzamide hybridsBioorganic Chemistry, 2022
- Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myelomaBioorganic & Medicinal Chemistry Letters, 2021
- Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPGCancer Cell, 2019
- Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitorsBioorganic & Medicinal Chemistry Letters, 2018
- ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute LeukemiaCancer Cell, 2018
- Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatmentEuropean Journal of Medicinal Chemistry, 2017